Orthofix Medical (NASDAQ:OFIX) Downgraded to “Hold” at StockNews.com

StockNews.com downgraded shares of Orthofix Medical (NASDAQ:OFIXGet Rating) from a buy rating to a hold rating in a research note released on Tuesday.

Other equities analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Orthofix Medical from a buy rating to a hold rating in a report on Thursday, March 3rd. TheStreet cut shares of Orthofix Medical from a c- rating to a d rating in a research note on Friday, February 25th. Finally, Stifel Nicolaus raised shares of Orthofix Medical from a hold rating to a buy rating and increased their target price for the company from $41.00 to $45.00 in a research report on Friday, March 4th.

Shares of OFIX stock opened at $26.69 on Tuesday. The company has a quick ratio of 1.76, a current ratio of 2.55 and a debt-to-equity ratio of 0.06. The company has a market cap of $529.88 million, a P/E ratio of -14.35 and a beta of 0.96. Orthofix Medical has a 52-week low of $26.15 and a 52-week high of $43.30. The stock has a 50-day moving average price of $32.32.

Orthofix Medical (NASDAQ:OFIXGet Rating) last released its earnings results on Friday, February 25th. The medical device company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.14. The company had revenue of $125.06 million during the quarter, compared to analyst estimates of $124.90 million. Orthofix Medical had a positive return on equity of 4.84% and a negative net margin of 8.26%. During the same period in the prior year, the company posted $0.44 earnings per share. As a group, research analysts predict that Orthofix Medical will post 0.66 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Lazard Asset Management LLC lifted its holdings in Orthofix Medical by 9.7% during the fourth quarter. Lazard Asset Management LLC now owns 3,820 shares of the medical device company’s stock valued at $118,000 after purchasing an additional 339 shares during the last quarter. Public Sector Pension Investment Board lifted its stake in shares of Orthofix Medical by 0.9% during the 4th quarter. Public Sector Pension Investment Board now owns 40,218 shares of the medical device company’s stock valued at $1,250,000 after buying an additional 350 shares in the last quarter. Captrust Financial Advisors lifted its stake in shares of Orthofix Medical by 47.6% during the 3rd quarter. Captrust Financial Advisors now owns 1,213 shares of the medical device company’s stock valued at $46,000 after buying an additional 391 shares in the last quarter. Marshall Wace North America L.P. purchased a new position in Orthofix Medical in the 1st quarter valued at approximately $25,000. Finally, Swiss National Bank grew its stake in Orthofix Medical by 1.4% in the 3rd quarter. Swiss National Bank now owns 43,200 shares of the medical device company’s stock valued at $1,647,000 after buying an additional 600 shares in the last quarter. 97.93% of the stock is owned by institutional investors.

About Orthofix Medical (Get Rating)

Orthofix Medical Inc operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures.

Featured Articles

Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.